Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Empagliflozin protects the heart against ischemia/reperfusion-induced sudden cardiac death
Authors
Keywords
-
Journal
Cardiovascular Diabetology
Volume 20, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-10-05
DOI
10.1186/s12933-021-01392-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association of SGLT2 inhibitors with arrhythmias and sudden cardiac death in patients with type 2 diabetes or heart failure: A meta-analysis of 34 randomized controlled trials
- (2021) Gilson C. Fernandes et al. HEART RHYTHM
- Mechanistic Insights of Empagliflozin in Nondiabetic Patients With HFrEF
- (2021) Juan Antonio Requena-Ibáñez et al. JACC-Heart Failure
- Load-independent effects of empagliflozin contribute to improved cardiac function in experimental heart failure with reduced ejection fraction
- (2020) Kim A. Connelly et al. Cardiovascular Diabetology
- Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat
- (2020) Sin-Hee Park et al. Cardiovascular Diabetology
- Empagliflozin prevents doxorubicin-induced myocardial dysfunction
- (2020) Jolanda Sabatino et al. Cardiovascular Diabetology
- Comparative efficacy of empagliflozin and drugs of baseline therapy in post-infarct heart failure in normoglycemic rats
- (2020) Marina Krasnova et al. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
- Acute dapagliflozin administration exerts cardioprotective effects in rats with cardiac ischemia/reperfusion injury
- (2020) Sarayut Lahnwong et al. Cardiovascular Diabetology
- SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
- (2020) Faiez Zannad et al. LANCET
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
- (2020) Christopher P. Cannon et al. NEW ENGLAND JOURNAL OF MEDICINE
- The sodium–glucose co-transporter 2 inhibitor empagliflozin attenuates cardiac fibrosis and improves ventricular hemodynamics in hypertensive heart failure rats
- (2019) Hsiang-Chun Lee et al. Cardiovascular Diabetology
- Sodium–glucose co‐transporter 2 inhibition with empagliflozin improves cardiac function in non‐diabetic rats with left ventricular dysfunction after myocardial infarction
- (2019) Salva R. Yurista et al. EUROPEAN JOURNAL OF HEART FAILURE
- Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics
- (2019) Carlos G. Santos-Gallego et al. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
- (2019) John J.V. McMurray et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin, a sodium glucose co-transporter-2 inhibitor, alleviates atrial remodeling and improves mitochondrial function in high-fat diet/streptozotocin-induced diabetic rats
- (2019) Qingmiao Shao et al. Cardiovascular Diabetology
- Empagliflozin attenuates ischemia and reperfusion injury through LKB1/AMPK signaling pathway
- (2019) Qingguo Lu et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)–TIMI 58 Trial
- (2018) Stephen D. Wiviott et al. AMERICAN HEART JOURNAL
- Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007–2017
- (2018) Thomas R. Einarson et al. Cardiovascular Diabetology
- Improvement in Cardiovascular Outcomes With Empagliflozin Is Independent of Glycemic Control
- (2018) Silvio E. Inzucchi et al. CIRCULATION
- Type 2 diabetes
- (2017) Sudesna Chatterjee et al. LANCET
- Ischemia/Reperfusion Injury following Acute Myocardial Infarction: A Critical Issue for Clinicians and Forensic Pathologists
- (2017) Margherita Neri et al. MEDIATORS OF INFLAMMATION
- Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
- (2017) Bruce Neal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mortality of Myocardial Infarction by Sex, Age, and Obstructive Coronary Artery Disease Status in the ACTION Registry–GWTG (Acute Coronary Treatment and Intervention Outcomes Network Registry–Get With the Guidelines)
- (2017) Nathaniel R. Smilowitz et al. Circulation-Cardiovascular Quality and Outcomes
- Remote Liver Ischemic Preconditioning Protects against Sudden Cardiac Death via an ERK/GSK-3β-Dependent Mechanism
- (2016) Zhaoyang Hu et al. PLoS One
- Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
- (2015) Bernard Zinman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Reperfusion Injury Salvage Kinase and Survivor Activating Factor Enhancement Prosurvival Signaling Pathways in Ischemic Postconditioning: Two Sides of the Same Coin
- (2010) Derek J. Hausenloy et al. ANTIOXIDANTS & REDOX SIGNALING
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started